A Vision for Growth
-
By
February 2, 2026
-
7 min
-
1
Novel therapies in ophthalmology are focusing on AMD, myopia, and dry eye disease.
-
2
The global ophthalmology drug market could reach $62 billion by
-
3
Gene therapy has begun to reshape treatment approaches for inherited retinal diseases.
-
4
Increased demand for clinical trials is expected to propel growth.
-
5
Collaborative consortia are vital for aligning clinical trial outcomes with regulatory needs.
-
6
Artificial intelligence is enhancing patient recruitment for trials and data analysis.
-
The future of ophthalmology is bound to be transformative with a focus on novel treatments for conditions like dry age-related macular degeneration and myopia. Recent trends suggest an increase in innovation and investment within the sector, despite challenges in the life sciences market. Companies are actively developing therapies, particularly for conditions such as AMD, diabetic retinopathy, and dry eye disease. Upcoming advancements, like gene therapies and artificial intelligence, are set to revolutionize patient care and clinical outcomes as the industry prepares for substantial growth leading into 2030.
-
1
Novel therapies in ophthalmology are focusing on AMD, myopia, and dry eye disease.
-
2
The global ophthalmology drug market could reach $62 billion by
-
3
Gene therapy has begun to reshape treatment approaches for inherited retinal diseases.
-
4
Increased demand for clinical trials is expected to propel growth.
-
5
Collaborative consortia are vital for aligning clinical trial outcomes with regulatory needs.
-
6
Artificial intelligence is enhancing patient recruitment for trials and data analysis.
Listen Tab content
